Edition:
United Kingdom

Aradigm Corp (ARDM.OQ)

ARDM.OQ on NASDAQ Stock Exchange Capital Market

1.48USD
18 May 2018
Change (% chg)

$0.06 (+4.23%)
Prev Close
$1.42
Open
$1.41
Day's High
$1.53
Day's Low
$1.41
Volume
821
Avg. Vol
47,811
52-wk High
$7.26
52-wk Low
$1.00

Select another date:

Thu, Apr 5 2018

BRIEF-Aradigm Announces EMA Has Completed Its Validation Of The MAA Submission

* ARADIGM ANNOUNCES THE EMA HAS COMPLETED ITS VALIDATION OF THE MAA SUBMISSION

BRIEF-Aradigm Reports Q4 Loss Per Share Of $0.28

* ARADIGM ANNOUNCES FOURTH QUARTER 2017 AND FULL YEAR FINANCIAL RESULTS

BRIEF-Aradigm Submits Marketing Authorisation Application To EMA For EU Marketing Approval Of Linhaliq

* ARADIGM SUBMITS MARKETING AUTHORISATION APPLICATION (MAA) TO EMA FOR EU MARKETING APPROVAL OF LINHALIQ IN NON-CYSTIC FIBROSIS BRONCHIECTASIS Source text for Eikon: Further company coverage:

BRIEF-FDA Declines To Approve Aradigm's Drug Linhaliq

* ARADIGM RECEIVES COMPLETE RESPONSE LETTER FROM THE FDA FOR LINHALIQ NDA

BUZZ-Aradigm Corp: Ladenburg Thalmann cuts rating to 'neutral'

** Drug developer's shares plunge 42.7 pct to $1.96 premarket - top pct loser among all U.S.-listed stocks

BRIEF-Aradigm - FDA Advisory Committee Did Not Recommend Approval For Linhaliq

* ARADIGM REPORTS RESULTS OF FDA ADVISORY COMMITTEE MEETING ON LINHALIQ‍​

BRIEF-Boxer Capital Reports 5.9 Pct Passive Stake In Aradigm Corp As Of Nov 30

* BOXER CAPITAL LLC REPORTS 5.9 PERCENT PASSIVE STAKE IN ARADIGM CORP AS OF NOVEMBER 30 - SEC FILING Source text: (http://bit.ly/2BDnINX) Further company coverage:

BRIEF-Aradigm Announces FDA Advisory Committee Meeting For Linhaliq

* ARADIGM ANNOUNCES FDA ADVISORY COMMITTEE MEETING FOR LINHALIQ

Select another date: